Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine

By Sahar G.   Berman M.   Ben-Gal T.   Sahar E.   Kogan A.   Michowitch R.   Saute M.   Kramer M.   Sagie A.   Shapira Y.   Aravot D.   Vidne B.A.  

Transplantation Proceedings, Vol. 35, Iss. 2, 2003-03 ,pp. : 678-678

Elsevier

Access to resources Recommend Favorite

Cytokine mRNA expression in tolerant heart allografts after immunosuppression with cyclosporine, sirolimus or brequinar

By Tian L.   Stepkowski S.M.   Qu X.   Wang M.-E.   Wang M.   Yu J.   Kahan B.D.  

Transplant Immunology, Vol. 5, Iss. 3, 1997-09 ,pp. : 189-198

Elsevier

Access to resources Recommend Favorite

Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes

By Kaibori M.   Okumura T.   Ito S.   Oda M.   Inoue T.   Kamiyama Y.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 804-805

Elsevier

Access to resources Recommend Favorite

Metabolic Effects of FK 506 (Tacrolimus) Versus Cyclosporine in Portally Drained Pancreas Allografts

By Elmer D.S.   Abdulkarim A.B.   Fraga D.   Shokouh-Amiri H.   Stratta R.J.   Hathaway D.K.   Reddy K.   Gaber A.O.  

Transplantation Proceedings, Vol. 30, Iss. 2, 1998-03 ,pp. : 523-524

Elsevier

Access to resources Recommend Favorite

Clinical trial of FK506 in heart transplant patients in taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506

By Ko W.J.   Chou N.K.   Chen Y.S.   Hsu R.B.   Wang S.S.   Chu S.H.  

Transplantation Proceedings, Vol. 30, Iss. 7, 1998-11 ,pp. : 3339-3341

Elsevier

Access to resources Recommend Favorite